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Abstract
Background: Our previous cDNA array results indicated KIAA0101 as one of the differentially
expressed genes in human hepatocellular carcinoma (HCC) as compared with non-cancerous liver.
However, it is necessary to study its expression at protein level in HCC and its biological function
for HCC cell growth.
Method:  Western blot and tissue array were performed to compare KIAA0101 protein
expression level in paired human HCC and non-cancerous liver tissues from the same patients.
Investigation of its subcellular localization was done by using dual fluorescence image examination
and enriched mitochondrial protein Western blot analysis. The in vitro cell growth curve was used
for examing the effect of over-expression of KIAA0101 in HCC cells. FACS was used to analyze
the cell cycle pattern in KIAA0101 expression positive (+) and negative (-) cell populations isolated
by the pMACSKKII system after KIAA0101 cDNA transfection.
Results: Western blot showed KIAA0101 protein expression was down-regulated in HCC tissues
as compared with their counterpart non-cancerous liver tissues in 25 out of 30 cases. Tissue array
also demonstrated the same pattern in 161 paired samples. KIAA0101 was predominantly localized
in mitochondria and partially in nuclei. KIAA0101 cDNA transfection could inhibit the HCC cell
growth in vitro. In cell cycle analysis, it could arrest cells at the G1 to S phase transition.
Conclusion: KIAA0101 protein expression was down-regulated in HCC. This gene could inhibit
the HCC cell growth in vitro and presumably by its blocking effect on cell cycle.
Background
Hepatocellular carcinoma (HCC) is one of the most prev-
alent and lethal cancer in Asia and Africa. The develop-
ment of HCC is a multi-factor in etiology, multi-step and
multi-gene involvement in carcinogenesis and progres-
sion. A broad spectrum of genes have been involved in
HCC development related to their genetic or epigenetic
alteration, including p53[1], p16, p21[2], p27[3], beta-
catenin[4], PTEN[5] and Rb etc. Recent studies on func-
tional genomics of HCC have further revealed that a
number of genes with novel sequences and unclarified
functions were involved in HCC development or progres-
sion [6]. Based on cDNA array, we found KIAA0101, now
designated as OEACT-1[7], as one of the genes with differ-
ential expression in HCC. In recent years, several reports
described that alteration of KIAA0101 expression
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occurred in several cancers including thyroid [7], non-
small cell lung cancer [8], and colon cancer [9]. This gene
was possibly related to some mechanisms regulating cell
proliferation and apoptosis [7,9].
Since the alteration of KIAA0101 expression reported so
far was based on mRNA transcription, we studied the
KIAA0101 protein expression level in human HCC as
compared with the matched non-cancerous liver tissues
by using an antibody prepared in our laboratory, and fur-
ther investigated its subcellular localization in HCC cells
and its biological effect on HCC growth and cell cycle.
We found that KIAA0101 was remarkably down-regulated
at protein level in HCC, and it was capable of inhibiting
cell growth and blocking the transition from G1 to S
phase in cell cycle.
Methods
Tissue samples and tissue array
The human liver cancer samples and matched adjacent
liver tissues were collected from the First Affiliated Hospi-
tal of Zhejiang University (Hangzhou, PR China). The
HCC cell lines were provided by our lab and cultured in
standard conditions (10% fetal bovine serum, 5% CO2).
Tissue array was prepared by our lab including 161 pairs
of liver cancerous tissues and adjacent non-cancerous tis-
sues, 13 liver cirrhosis tissues and 10 normal livers. All
samples of collection were under consensus agreements,
and were approved by the Ethical Review Committee of
the World Health Organization Collaborating Center for
research in Human Production.
Antibody preparation
KIAA0101 coding sequence was subcloned into the
pEGFP plasmid and pET-32a prokaryotic expression vec-
tor (His tag) separately and sequenced for confirmation.
The primers for pEGFP vector are 5-ggagatctaacatggtgcg-
gactaaag-3 and 5-gggtcgaccattctttttcatcatttg-3; the primers
for pET-32a are 5-ggggatccgcaacatggtg cggactaaag-3 and 5-
ggctcgagttctttttcatcatttg-3. The sequence underlined is
restriction site for subcloning. Then the pET-32a+0101
recombinant expression plasmid was transformed into
competent BL21 cells. Following induction of BL21 cells
with 0.4 mM IPTG at 37°C for 4 hours, then the whole
cells were lysised by the suspersonic equipment. The
supernatant including the cell whole proteins were flowed
through the Ni-coated column and the His-KIAA0101
fusion proteins were bound. After three times wash of the
column, the His-KIAA0101 fusion protein was obtained
by the elution buffer and was used for rabbit polyclonal
antibody production according to the standard procedure.
Western blotting
The liver tumor and non-tumor samples were lysised in T-
PER tissue protein extraction reagent (PIERCE) containing
proteinase inhibitor cocktail (Roche) in 4°C for 30 min-
utes. The debris was discarded and the supernatant
including whole proteins were quantified by BCA kit
(PIERCE) and subjected to 15% SDS-PAGE (40 ug). Next
the proteins were transferred onto a nitrocellulose mem-
brane (Schleicher & Schuell BioScience) and this mem-
brane was blocked by the 5% milk dissolved in PBST for
an hour. After incubation with the fist antibody and sec-
ond antibody sequencely, detection was performed by
using an ECL system (PIERCE). The rabbit anti-KIAA0101
antibody was used (1:1000) and GFP antibody (1:1000).
Anti-β-actin antibody (1:10000, Sigma) was used as inter-
nal control.
Immuno-histochemistry
The tissue array plate was blocked with 3% BSA 37°C for
1 hour, then probed with KIAA0101 antibody (1:100) at
4°C in a humidified chamber for 12 hours, followed
rinsed three times by PBS and incubated with secondary
rabbit antibody for 1 hour at 37°C (1:1000). This anti-
body complex was visualized by 3, 30-diaminobenzidine
(Zymed Laboratories Inc.). Sections were counterstained
with hematoxylin for 5 min and mounted with Eukit (Cal-
ibrated Instrument). The result was observed under a light
microscope, and a semi-quantitative score for intensity
was given to the different samples: +++, ++, + and -.
Dual immuno-fluorescence and enriched mitochondrial 
protein Western blot
Cultured HCC cells were seeded on the cover slips and
incubated for 12 hours. Then the cells were probated with
IgG-purified anti-KIAA0101 primary antibody (1:100) for
half an hour in 37°C, after three times wash by PBS, the
cells were incubated with TRITC-conjugated goat anti-rab-
bit secondary antibody for an hour. Also the same cover
slip were washed and antibody angnist cytochrome oxi-
dase I was added at 1 mg/ml in block buffer, followed by
FITC-conjugated goat anti-mouse IgG at 15 mg/ml in
block buffer. The cells were viewed by epi-fluorescence
with Axioskop 2 universal microscope. Digital images
were captured using a CCD camera and analysized by ISIS
system.
For enriched mitochondrial protein Western blot, cells
were rinsed twice with cold PBS and then lysed in radio-
immune precipitation (RIPA) buffer for 15 min at 4°C.
Cell lysates were clarified by centrifugation at 10,000 rpm
for 10 min, and the supernatant was incubated with 1 ug
anti-mitochondrial antibody (Neomarks) for overnight in
4°C. Then the immune complexes were precipitated by
protein A/G-Sepharose beads and washed four times withBMC Cancer 2006, 6:109 http://www.biomedcentral.com/1471-2407/6/109
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RIPA buffer, followed separated by 15% SDS-PAGE elec-
trophoresis and for the KIAA0101 Western blot.
Co-transfection and separation of transient expression 
cells
Transfection was performed by incubating cells with
pcDNA3.1/A+0101 together with the pMACS KKII plas-
mid (5:1) (Miltenyi Biotec, Auburn, CA, USA). pMACS
KKII plasmid could be provided for the magnetic isolation
of transiently transfected mammalian cells. Briefly, 4*106
cells in 6-cm plate were incubated for 5 hours at 37°C
with 5 ug of the plasmid pcDNA3.1/A+0101 and 1 ug of
pMACS KKII magnetic plasmid in a total of 1 ml DMEM.
The cells were then washed and incubated overnight in
DMEM containing 10% FCS at 37°C in 5% CO2 atmos-
phere. 48 hours later, the cells were labeled by MACSselect
KKII microbeads and selected by MACSselect KKII column
according to the protocol recommended. At the same
time, the co-transfection of pcDNA3.1/A with pMACS
KKII plasmids into cells is performed as control.
Cell growth analysis
KIAA0101 transiently expression positively (+) cells iso-
lated by the MACSselect KKII microbeads and negative
cells were seeded into 96-well flat-bottom microtiter
plates equally. Cells were cultured in DMEM containing
10% FBS. Each day, 10 ul of CKK-8 solution (Dojin,
Osaka, Japan) were added to each well and incubated for
2 hrs at 37°C. Optical density was read at 450 nm in a
microplate reader.
Cell cycle analysis
KIAA0101 transiently expression positively (+) cells iso-
lated by the MACSselect KKII microbeads and negative
cells were fixed in PBS/70% EtOH at -20°C overnight. On
the following day, cells were washed in PBS, stained with
propidium iodide (50 mg/ml) and RNAse (360 mg/ml)
for 30 min at 37°C, then with just propidium iodide (50
mg/ml) in PBS for at least 1 h at 4°C. DNA content was
quantified using a FACSCAN (Becton Dickson). This
experiment was repeated three times.
Results
Preparation of polyclonal antibody against KIAA0101 and 
test of its specificity
As the antibody for KIAA0101 was not commercial avail-
able, we prepared the polyclonal rabbit antibody against
full-length KIAA0101-His fusion protein. The
pEGFP+0101 recombinant plasmid was constructed and
transfected into HCC cells. The proteins of the transfected
cells were extracted for Western blot by using the anti-GFP
antibody and KIAA0101 rabbit antibody to test the
expression of EGFP and KIAA0101. As illustrated in Fig 1,
a band of EGFP-KIAA0101 fused protein could be
revealed by both the anti-GFP and anti-KIAA0101 anti-
bodies. On the contrary, no band was observed for pEGFP
vector-transfected cell protein by anti-KIAA0101 anti-
body, though it was positive by anti-GFP antibody. Also
we used the KIAA0101 prokaryotic expression for the test
of its antibody specificity. The KIAA0101 antibody could
detect a specific band with the predicted size (15 KD) and
Western blot for testing the specificity of prepared rabbit KIAA0101 antibody Figure 1
Western blot for testing the specificity of prepared rabbit KIAA0101 antibody. A: the recombinant pEGFP+0101 and pEGFP 
plasmids were transfected into cells separately. 48 hours later, the transfected cell protein were extracted for Western blot 
analysis with GFP antibody (1:1000) and prepared rabbit KIAA0101 antibody (1:1000) respectively. B: the KIAA0101 prokaryo-
tic expression protein was loaded at different quantity (10 ng, 5 ng and 2 ng) and reacted for the test of the prepared 
KIAA0101 antibody specificity.BMC Cancer 2006, 6:109 http://www.biomedcentral.com/1471-2407/6/109
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the intensity of band signal was generally proportional to
the amount of loaded protein. Therefore, we concluded
that our prepared rabbit polyclonal antibody for
KIAA0101 was specific, and it could be used for further
experiments.
KIAA0101 protein was down-regulated in HCC
To demonstrate KIAA0101 expression pattern at the pro-
tein level in human HCC, 30 human HCC (T) and
matched noncancerous liver tissues (NT) from the same
patients were analyzed by Western blot (Figure 2). The
protein band intensity was compared after being normal-
ized with that of the beta-actin internal control. It was
striking that the protein expression level of KIAA0101 in
HCC tissues was reduced as compared with that of non-
cancerous tissues among 25 out of 30 paired samples. We
have conducted the tissue array by immunohistochemical
survey(ISH) for further validation. Fig 3 illustrated the dif-
ferent intensity between HCC and matched non-cancer-
ous tissues, liver cirrhosis and normal liver tissues by ISH
method. As demonstrated in table 1 (see Additional file
1), the tissue array showed the signal intensity was
weak(+) or negative(-) in 107 out of 161 HCC tissues;
while the weak (+) or negative (-) signals were seen in
only 24 out of 161 samples of non-cancerous liver tissues.
Therefore, the KIAA0101 protein expression was much
lower in the HCC tissues as compared with the non-can-
cerous tissues (p < 0.01). In addition, in 8 out of 13 of
liver cirrhosis tissues and all 10 normal liver tissues,
KIAA0101 protein was expressed varying from moder-
ate(++) to high(+++) level. However, the KIAA0101 pro-
tein level in HCC tissues was obviously reduced.
Furthermore, we have attempted to investigate if the
down-regulation of KIAA0101 protein expression had any
correlation with the patients' background information,
such as age, sex, histopathological grading, tumor size and
HBV infection. However, we have not found any signifi-
cant association between the clinical or pathological state
of HCC with the KIAA0101 expression (see Additional file
2).
Localization of KIAA0101 in mitochondria
The bioinformatics has implicated that KIAA0101 was
possibly localized in mitochondrial. To verify this predic-
tion, we have performed immuno-fluorescence survey on
SMMC7721 cells by using the polyclonal rabbit antibody.
KIAA0101 immuno-fluorescence was exhibited in a
speckled pattern in the cytoplasm. The distribution of
KIAA0101 immuno-fluorescence appeared to be similar
to the distribution of mitochondria. In dual-labeling
experiments, KIAA0101 immuno-fluorescence partially
coincided with the image generated by a labeled mono-
clonal antibody that recognized cytochrome oxidase sub-
unit I, an inner mitochondrial membrane protein. The
partially co-localization of KIAA0101 with mitochondrial
proteins suggested that KIAA0101 was localized predom-
inantly in mitochondria (Fig 4). Meanwhile, we used the
specific mouse anti-mitochondrial (Neomarkers) to
enrich the mitochondrial proteins from total cell proteins
preparation. After precipitated by the protein A/G beads,
the enriched mitochondrial proteins were subjected to
Western blot for KIAA0101 in HCC and counterpart non- cancerous liver tissues Figure 2
Western blot for KIAA0101 in HCC and counterpart non-
cancerous liver tissues. To investigate KIAA0101 protein 
expression level, 30 pairs of tumor and non-tumor liver tis-
sues were analyzed. The KIAA0101 protein expression was 
lower in 25 out of 30 HCC tissues as compared with non-
cancerous liver tissue (N: non-cancerous tissue; T: tumor tis-
sue). Beta-actin was used an internal control.
KIAA 0101 expression in tissue array was analyzed by immu- nohistochemistry (ISH) examination Figure 3
KIAA 0101 expression in tissue array was analyzed by immu-
nohistochemistry (ISH) examination. The tissue array 
showed different levels of KIAA0101 protein expression in 
paired HCC and non-cancerous tissues, liver cirrhosis and 
normal liver tissues by ISH method. Weak expression of 
KIAA0101 was observed in HCC; while strong expression in 
its counterpart non-cancerous liver tissue. In 8 out of 13 liver 
cirrhosis and all 10 normal liver tissues, KIAA0101 protein 
expression level were strong(+++) or moderate(++) level.BMC Cancer 2006, 6:109 http://www.biomedcentral.com/1471-2407/6/109
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Western blot with KIAA0101 rabbit antibody. Fig 5
showed that there were strong signal in lanes loaded by
enriched mitochondrial proteins; however, there were
only very weak signal in the un-sorted total cell proteins.
From these two different experiments, we could conclude
that the KIAA0101 protein was predominantly located in
the mitochondria of human HCC SMMC 7721 cells.
Cell growth and cell cycle analysis
For better understanding if the KIAA0101 has any effect
on cell growth, we employed the pMACS KKII system to
isolate the KIAA0101 over-expressed cells after transient
KIAA0101 cDNA transfection into two different HCC cell
line: Hep3B and HepG2. The isolated KIAA0101 expres-
sion positive (+) cells and the KIAA0101 negative (-) con-
trol cells were seeded into the 96-well plate. We measured
the absorbance at the 450 nm with the CCK-8 kit each
day. As illustrated in Fig 6, the KIAA0101 over-expression
could inhibit the growth of both HCC cell line: HepG2
and Hep3B (P < 0.05). Meanwhile, as indicated in Fig 7A,
the sorted KIAA0101 expression positive and negative
cells were analyzed by FACS and the results demonstrated
that the cell population at S phase of KIAA0101 positive
cells was reduced by nearly 8% as compared with the neg-
ative cells and the difference had statistical significance(P
< 0.05). The percentage of G0/G1 phase in KIAA0101 pos-
itive (+) cells is 64.38% ± 1.46, while in negative cells the
proportion of phase G0/G1 is 54.7% ± 1.43. The differ-
ence was of statistical significance (p < 0.05, Fig 7B). The
percentage of G2/M phase in KIAA0101 positive (+) cells
is 14.69% ± 0.62 while in negative cells the proportion is
15.21% ± 0.51 with no statistical difference (Fig 7C).
Taken together, the FACS result was well consistent with
the retardation of HCC cell growth after over-expression
of KIAA0101 protein.
Discussion
KIAA0101 has been recently reported as a novel gene
related to thyroid [7], non-small cell lung carcinoma[8]
and colon cancer[9,10]. In these reports, the alteration of
expression at mRNA level was documented, either up-reg-
ulated [7-9] or down-regulated [10] in cancers described.
Transient expression of KIAA0101 protein inhibited the  HCC cell growth in virto (p < 0 Figure 6
Transient expression of KIAA0101 protein inhibited the 
HCC cell growth in virto (p < 0.05). pcDNA3.1/A+0101 and 
pMACSKKII plasmids were co-transfected into the HepG2 
and Hep3B cells. Meanwhile, the pcDNA3.1/A and pMACSK-
KII plasmids were co-transfected and isolated as control. 
After about 48 hours, the KIAA0101 expression positive 
cells were selected by magnetic microbeads through column 
and seeded into 96-well plates. At every 24 hours, the cells' 
growth absorbance was measured with CCK-8 kit.
Western blot for KIAA0101 protein in mitochondrial- enriched protein fraction and total cell proteins (1 and 2  were mitochondrial enriched proteins from SMMC 7721 and  HepG2 respectively; 3 and 4 were total cell protein from  SMMC 7721 and HepG2 respectively) Figure 5
Western blot for KIAA0101 protein in mitochondrial-
enriched protein fraction and total cell proteins (1 and 2 
were mitochondrial enriched proteins from SMMC 7721 and 
HepG2 respectively; 3 and 4 were total cell protein from 
SMMC 7721 and HepG2 respectively).
Localization of KIAA0101 predominantly in mitochondria Figure 4
Localization of KIAA0101 predominantly in mitochondria. 
HCC SMMC 7721 Cells were seeded on slip for dual immun-
ofluorescence analysis. Primary antibodies for cytochrome 
oxidase I and KIAA0101 were detected using FITC- and 
TRITC- conjugated secondary antibodies, respectively. Yel-
low fluorescence in the overlay image indicated the co-locali-
zation of the red fluorerscence of KIAA0101 with the green 
fluorescence of mitochonriion specific of cytochrome oxi-
dase I.BMC Cancer 2006, 6:109 http://www.biomedcentral.com/1471-2407/6/109
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The data presented here is the first time to demonstrate
the alteration of KIAA0101 expression at protein level in
human HCC by using Western analysis of 30 paired
human HCC and non-cancerous liver tissues. KIAA0101
down-regulated expression at protein level was observed
in 25 HCC tissues (83%). Utilizing tissue array and
immunohistochemical survey, it was also demonstrated
that no (-) or very weak (+) signals were detected in 107
HCC tissues (T) of 161 paired HCC (T) and non-cancer-
ous (NT) tissues (66.4%). These data demonstrated that
KIAA0101 expression at the protein level was remarkably
down-regulated in HCC based on both Western and tissue
array analysis.
We have attempted to correlate the expression status of
KIAA0101 with the clinic-pathological background and
HBV infection. However, we have not obtained positive
association between KIAA0101 expression and etiology-
clinial state(see Additional file 2). It implicated that
KIAA0101 might be presumably one of the genes essential
for cell growth basic machinery which was less dependent
on different etiological or differentiation status. However,
the further correlation study should be necessary to survey
in a much larger scale of case population.
For better understanding the possible biological effect of
KIAA0101 relevant to the growth behavior of cells, we
examined the effect of over-expression of KIAA0101 after
transfection into two different cell lines using growth
curve assays. Our data indicated an inhibiting effect on
cell growth of both these HCC cell lines. These results
seemed not apparently consistent with the previous
reports in thyroid cancer[7] and HEK293 cells[9]. The
KIAA0101 mRNA expression in thyroid cancer was up-
regulated and knock down of its expression by siRNA
could retard the cell growth [7], while the over-expression
The percentage of G0/G1, S and G2/M phase in the isolated KIAA0101 expression positive (+) cells and negative cells Figure 7
The percentage of G0/G1, S and G2/M phase in the isolated KIAA0101 expression positive (+) cells and negative cells. The 
KIAA0101 transiently expressed cells were separated by the magnetic beads through the pMACS column and analyzed by the 
FACS. At the same time, the KIAA0101 expression negative cells were done as control. A: The percentage of S phase in 
KIAA0101 positive (+) cells is 21.35% ± 1.28; while in negative cells the proportion of S phase is 29.45% ± 1.45 (P < 0.05). B: 
The percentage of G0/G1 phase in KIAA0101 positive (+) cells is 64.38% ± 1.46; while in negative cells the proportion of phase 
G0/G1 is 54.7% ± 1.43 (P < 0.05). The percentage of G2/M phase in KIAA0101 positive (+)cells is 14.69% ± 0.62; while in neg-
ative cells the proportion of G2/M phase is15.21% ± 0.51. These results indicated the KIAA0101 could inhibit cell cycle transi-
tion from G1 to S phase.BMC Cancer 2006, 6:109 http://www.biomedcentral.com/1471-2407/6/109
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of KIAA0101 by cDNA transfection in HEK293 cells had
no effect on cell growth on this immortalized human
renal cells[9]. Our data did demonstrate that KIAA0101
over-expression could retard the cell growth of human
HCC cells. These data were further supported by the
results of cell cycle analysis which indicated the arrest at
G1/S transition in KIAA0101 over-expressed cells. The
inconsistency between our data and those from other lab-
oratories might be attributed to different types of cancers
or cells used for studies. It is probable that KIAA0101
might have different expression pattern in various types of
cancers. Also the possibility that KIAA0101 may play var-
ious biological roles in different types of normal and can-
cer cells could not be excluded. Moreover, the discrepancy
of data between level of mRNA and protein expression in
the same tissue has been reported[11]. In chen's report,
they compared the level of mRNA with protein expression
among 165 proteins. A subset of proteins demonstrated a
negative correlation with the mRNA expression value.
Thus the possibility that a negative correlation existed
between KIAA0101 mRNA with protein level could not be
excluded. It may also interpret, at least in part, the contro-
versial data about mRNA and protein expression of
KIAA0101 genes from different laboratories.
In our observation, the KIAA0101 gene product was pre-
dominantly localized in mitochondria of human HCC
cells, but the minor portion was found in nuclei. A recent
report by Simpson F etal has described that KIAA0101 was
predominantly found in mitochondria of human renal
HEK293 cells, but it could translocate into nuclei after UV
exposure. It was found that KIAA0101 could bind to
PCNA and a putative tumor suppressor[9]. Therefore, the
KIAA0101 may have a complex feature in its signal path-
way and further studies of KIAA0101 are needed to
explore its signal pathway in human HCC cells.
Taken together, our findings may put some insight on fur-
ther elucidation of KIAA0101 in regulatory mechanism of
cell growth and its relevance to HCC development and
progression.
Conclusion
This is the first report to demonstrate the down-regulation
of KIAA0101 at protein level in human HCC and its over-
expression could inhibit the human HCC cell growth.
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